PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
9.62%
Cash & equivalents growing 9.62% while AVXL's declined -4.81%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
9.62%
Below half of AVXL's -4.81%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.08%
Below half of AVXL's -4.09%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.18%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.96%
Higher Long-Term Investments Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.38%
Below half of AVXL's -100.00%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
8.48%
Below half of AVXL's -4.09%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-5.53%
Above 1.5x AVXL's -0.69%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-100.00%
Higher Short-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
6569.50%
Higher Deferred Revenue (Current) Growth compared to AVXL's zero value, indicating better performance.
100.00%
Higher Other Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
-5.06%
Above 1.5x AVXL's -0.31%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2126.46%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.39%
Above 1.5x AVXL's -0.12%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-1.27%
Above 1.5x AVXL's -0.31%. Michael Burry sees a potential leverage warning sign.
3.57%
Higher Common Stock (Book Value) Growth compared to AVXL's zero value, indicating worse performance.
-2.57%
0.75-0.9x AVXL's -2.94%. Bill Ackman questions if competitor reinvests profits more robustly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.56%
Below half AVXL's -4.43%. Michael Burry sees potential underperformance in building shareholder capital.
8.48%
Below half AVXL's -4.09%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.96%
Higher Total Investments Growth compared to AVXL's zero value, indicating better performance.
-6.20%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
-10.07%
Less than half of AVXL's 4.81%. David Dodd sees better deleveraging or stronger cash buildup than competitor.